Document is current
Any future updates will be listed below
-
Authors
Brod, Meryl https://orcid.org/0000-0002-0663-5838
Pfeiffer, Kathryn M. https://orcid.org/0000-0003-2186-6340
Beck, Jane F. https://orcid.org/0000-0003-1880-1933
Smith, Alden https://orcid.org/0000-0003-1582-534X
-
Funding
Funding for this research was provided by:
Ascendis Pharma Bone Diseases A/S (NA)
- License Information
-
More Information
Article History
Received: 8 January 2024
Accepted: 3 July 2024
First Online: 13 August 2024
Declarations
:
: The exit interview study was part of the PaTHway trial protocol and Institutional Review Board (IRB) review and approval. Participating sites' ethics approvals: McMaster University, Central IRB Advarra Canada (#SSU00143192); Queen Elizabeth II Health Sciences Centre- Victoria General, Nova Scotia Health Research Ethics Board, Centre for Clinical Research (#1026613); Duchossois Center for Advanced Medicine- Hyde Park, The University of Chicago IRB (#IRB20-1802); Columbia University Medical Center-Harkness Pavilion, Columbia University IRB (#IRB-AAAT5133); Mayo Clinic-Rochester, Mayo Clinic IRB (#20-010914); University of California San Francisco, Central IRB (Advarra)(#SSU00140830); Northern Nevada Endocrinology, Central IRB (Advarra) (#SSU00140374); Texas Diabetes and Endocrinology- Central Austin, Central IRB (Advarra) (#SSU00137378); Arthritis Northwest, PLLC, Central IRB (Advarra) (#SSU00139662); Physicians East-WH Smith Boulevard, Central IRB (Advarra) (#SSU00137883). Informed consent was obtained from all study participants.
: Not applicable.
: MB, KMP, and JFB are consultants to the pharmaceutical industry, including Ascendis Pharma, Inc. AS is an employee of Ascendis Pharma, Inc.
